Life-threatening fungal infections in patients with diabetes mellitus: Treatment with amphotericin B lipid complex

Infectious Diseases in Clinical Practice

Volumn 6, Issue 8, 1997, Pages 537-542

  Baddour, Larry M ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; CHILL; CLINICAL ARTICLE; CRYPTOCOCCOSIS; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEADACHE; HISTOPLASMOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY;

EID: 0030687905     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199706080-00009     Document Type: Article

References (20)

1. Perschel WT, Langefeld TW, Federlin K. Susceptibility to infections in diabetes - effects on metabolism. Immun Infekt 1995;23:196-200.
2. Schubert S, Heesemann J. Infections in diabetes mellitus. Immun Infekt 1995;23:200-4.
3. Vazquez JA, Sobel JD. Fungal infections in diabetes. Infect Dis Clin North Am 1995;9:97-116.
4. Sarosi GA. Amphotericin B. Still the "gold standard" for antifungal therapy. Postgrad Med 1990;88:151-66.
5. Graybill JR. The future of antifungal therapy. Clin Infect Dis 1996;22(2 Suppl):S166-S178.
6. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals; prevention and management. Drug Saf 1992;7:323-63.
7. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Nad Acad Sci USA 1988;85:6122-6.
8. Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (ABLC 228): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3:451-71.
9. Hiemenz JW, Lister LW, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. Blood 1995;86:A3383.
10. ®) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996;56:18-23.
11. Smitherman KO, Peacock JE Jr. Infectious emergencies in patients with diabetes mellitus. Med Clin North Am 1995; 79:53-77.
12. Garrison MW, Campbell RK. Identifying and treating common and uncommon infections in the patient with diabetes. Diabetes Educ 1993;19:522-31.
13. Baxter JK, Babineau TJ, Apovian CM, et al. Perioperative glucose control predicts increased nosocomial infection in diabetics. Crit Care Med 1990;18:5707.
14. Shpitzer T, Stern Y, Anavi Y, Segal K, Feinmesser R. Mucormycosis: experience with 10 patients. Clin Otolaryngol 1995;20:374-9.
15. Tierney MR, Baker AS. Infections of the head and neck in diabetes mellitus. Infect Dis Clin North Am 1995;9:195-216.
16. Arris WM, Fountain JA, Delcher HK, Jones HE A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982, 31:1109-114.
17. Naguib MT, Huycke MM, Pederson JA, Pennington LR, Burton ME, Greenfield RA. Apophysomyces elegans infection in a renal transplant recipient. Am J Kidney Dis 1995;26:381-4.
18. Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis: therapy with amphotericin B lipid complex. Arch Intern Med 1996;156:337-9.
19. Agodoa LY, Jones CA, Held PJ. End-stage renal disease in the U.S.A.: data from the United States Renal Data System. Am J Nephrol 1996;16-7-16.
20. Lippert J, Ritz E, Schwarzbeck A, Schneider P. The rising tide of end-stage renal failure from diabetic nephropathy type II - an epidemiological analysis. Nephrol Dial Transplant 1995;10:462-7.